Safety Profile

Retatrutide Side Effects & Safety

Retatrutide Phase II data shows GI side effects similar to tirzepatide, slightly more intense due to triple receptor activity.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

Side effects by severity

Serious1 effect

MTC risk (rodent)

Standard incretin-class rodent signal; human relevance uncertain.

Common5 effects

Nausea

35-50%

Most prominent in titration phase.

Diarrhea

20-33%

Dose-related.

Vomiting

15-30%

More common at higher doses.

Decreased appetite

Expected pharmacological effect.

Increased heart rate

Average 5-10 bpm increase — related to glucagon receptor activation.

Uncommon2 effects

Injection site reactions

Mild redness or itching.

Gallbladder disease

Associated with rapid weight loss.

Rare1 effect

Pancreatitis

Standard incretin class concern.

Contraindications

Personal or family history of MTC
MEN 2 syndrome
Known hypersensitivity

Drug interactions

Insulin and sulfonylureas — increased hypoglycemia risk
Oral medications with narrow therapeutic index

Special populations

Phase III ongoing; not FDA approved. Pregnancy data limited; not recommended.

Safety summary

Retatrutide is under active investigation; current Phase II data shows GI side effects consistent with incretin class. The unique heart rate increase warrants monitoring, especially in patients with pre-existing CV disease.

Frequently asked

Why does retatrutide raise heart rate?

Glucagon receptor activation (the third receptor targeted by retatrutide) increases heart rate. This effect is modest (5-10 bpm) but should be considered in patients with existing tachyarrhythmias.